Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Cassidy, Sophie ^a   Hallsworth, Kate ^a   Thoma, Christian ^a   MacGowan, Guy A ^a,b   Hollingsworth, Kieren G ^a   Day, Christopher P ^a   Taylor, Roy ^a   Jakovljevic, Djordje G ^a   Trenell, Michael I ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Cardiac disease; Non alcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHOLESTEROL; CREATINE PHOSPHATE; GLUCOSE; HEMOGLOBIN A1C; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CARDIAC STRAIN; CARDIAC STRUCTURE; CARDIAC TORSION; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART; HEART DISEASE; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; INTRAABDOMINAL FAT; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; SYSTOLIC BLOOD PRESSURE; VENOUS OXYGEN TENSION; AGED; BLOOD; CINE MAGNETIC RESONANCE IMAGING; DIABETES MELLITUS, TYPE 2; GLYCEMIC INDEX; HEART VENTRICLE REMODELING; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY; PROCEDURES; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; VENTRICULAR REMODELING;

EID: 84924334674     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0187-2     Document Type: Article

References (40)

1. International Diabetes Federation. IDF diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.
3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-31.
4. Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, Forouhi NG, et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes. 2007;56:984-91.
5. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734-43.
6. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510:84-91.
7. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974;23:105-11.
8. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234-8.
9. National Diabetes Audit Report 2: Complications and Mortality. Health and social care information centre. 2013. http://www.hscic.gov.uk/searchcatalogue?productid=13413&q=national+diabetes+audit&sort=Relevance&size=10&page=1#top ]
10. Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum γ-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99:163-7.
11. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54:1524-32.
12. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, et al. Diastolic dysfunction is associatedwith altered myocardial metabolism inasymptomatic normotensive patientswith well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42:328-35.
13. Venskutonyte L, Jarnert C, Rydén L, Kjellström B. Longitudinal development of left ventricular diastolic function in patients with type 2 diabetes. Diabetes Care. 2014;37:3092-7.
14. Graça B, Donato P, Ferreira MJ, Castelo-Branco M, Caseiro-Alves F. Left ventricular diastolic function in type 2 diabetes mellitus and the association with coronary artery calcium score: a cardiac MRI study. Am J Roentgenol. 2014;202:1207-14.
15. Fonseca CG, Dissanayake AM, Doughty RN, Whalley GA, Gamble GD, Cowan BR, et al. Three-dimensional assessment of left ventricular systolic strain in patients with type 2 diabetes mellitus, diastolic dysfunction, and normal ejection fraction. Am J Cardiol. 2004;94:1391-5.
16. Korosoglou G, Humpert PM, Ahrens J, Oikonomou D, Osman NF, Gitsioudis G, et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging. 2012;35:804-11.
17. Marciniak C, Marechal X, Montaigne D, Neviere R, Lancel S. Cardiac contractile function and mitochondrial respiration in diabetes-related mouse models. Cardiovasc Diabetol. 2014;13:118.
18. Lamberts RR, Lingam SJ, Wang H-Y, Bollen IA, Hughes G, Galvin IF, et al. Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovasc Diabetol. 2014;13:72.
19. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40:949-55.
20. Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59:461-70.
21. Nakamori S, Onishi K, Nakajima H, Yoon YE, Nagata M, Kurita T, et al. Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging. Circ J. 2012;76:2234-40.
22. Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, Macgowan GA, Anstee QM, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2012;58:1-6.
23. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55:2005-23.
24. Jones DEJ, Hollingsworth K, Fattakhova G, MacGowan G, Taylor R, Blamire A, et al. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2010;298:G764-73.
25. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278-83.
26. Vanninen E, Mustonen J, Vainio P, Länsimies E, Uusitupa M. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol. 1992;70:371-8.
27. Missouris CG, Forbat SM, Singer DR, Markandu ND, Underwood R, MacGregor GA. Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension. J Hypertens. 1996;14:1005-10.
28. Adeghate E, Singh J. Structural changes in the myocardium during diabetes-induced cardiomyopathy. Heart Fail Rev. 2014;19:15-23.
29. Hollingsworth KG, Blamire AM, Keavney BD, Macgowan GA. Left ventricular torsion, energetics, and diastolic function in normal human aging. Am J Physiol Heart Circ Physiol. 2012;302:H885-92.
30. Halley CM, Houghtaling PL, Khalil MK, Thomas J, Jaber W. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med. 2011;171:1082-7.
31. Lumens J, Delhaas T, Arts T, Cowan BR, Young AA. Impaired subendocardial contractile myofiber function in asymptomatic aged humans, as detected using MRI. Am J Physiol Heart Circ Physiol. 2006;291:H1573-9.
32. Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, et al. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:38.
33. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668-73.
34. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med. 1992;117:502-10.
35. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res. 1999;43:344-53.
36. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040-6.
37. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47:51-8.
38. Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease | 1-Recommendations | Guidance and Guidelines | NICE. NICE; 2014:CG181.
39. Rijzewijk LJ, van der Meer RW, Smit JWA, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793-9.
40. Ng ACT, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation. 2010;122:2538-44.